Building the Pathway for a First-In-Class Oncology Launch
Signal · Physician Engage · Expert Exchange · Lab Engage
When There’s No Pathway, You Have to Build One
Rare biomarker testing, patient identification and precision medicine commercialization, a first-in-class oncology launch story.
This particular gene fusion affects fewer than 1% of solid tumor patients, scattered thin across a small number of tumor types. When the client launched a first-in-class therapy targeting it, the commercial challenge wasn't finding patients on an existing pathway. There was no pathway.
NO COMMERCIAL INFRASTRUCTURE
NO CLINICAL AWARENESS
POSITIVE PATIENTS, HARD TO FIND IN TIME
Even where a positive result existed, the patient was one of a handful scattered across the US. Finding the patient at the clinical decision point was its own problem, separate from testing altogether.
WRONG TESTING METHODOLOGY
Build the Market. Find the Patients. Connect the Dots
Diaceutics deployed the full Relay suite including Lab Engage and Physician Engage to shift testing behavior, Signal for real-time patient identification, and Expert Exchange for physician awareness, working on all four from day one. None of the four worked in isolation, testing, awareness and identification data continuously informed each other, which is exactly what running one connected system delivers that three separate point solutions can't.
Lab capability and physician education, through Lab Engage and Physician Engage Targeted DNA-to-RNA testing behavior change across 7,414 physicians and labs. Every lab that gained RNA capability during the program had already been targeted by Diaceutics, a claim no competitor in the category currently makes.
Real-time Signal alerts Daily patient-level Signal alerts to testing physicians, engaging them within 24 hours of the alert landing following a confirmed positive result - identifying the patient before the treatment decision was made, not after.
Expert Exchange Peer-to-peer pathology expert conversations through Expert Exchange triggered directly by Signal - reaching the right physician before the prescribing window closed.
VP Marketing
patients tested
74,820 patients were tested across the program in 16 months, achieving a 100% testing rate in one of the rarest biomarker populations in oncology. Testing volumes also grew by *19.6% in the most recent six months versus the first six months, showing that Diaceutics did not simply deliver a one-time testing milestone, but built a program that continues to identify patients and generate value as the market matures.
unique HCPs targeted
>10,000 unique HCPs targeted with educational messaging on NRG1 testing best practices, open and click rates above industry average, driving the testing behaviour change measured across the programme.
of physicians
of physicians with a confirmed biomarker-positive patient had a direct conversation with a pathology expert at the point the clinical decision was being made, not after it.
of physicians had poor or average awareness of this biomarker before their first Expert Exchange conversation (large stat, left-aligned, single stat graphic right-aligned), the scale of the gap Expert Exchange exists to close. ~75% of physicians with a successful engagement were subsequently linked to ordering accounts.
of physicians
~63% of all invoiced client accounts, some spanning multiple physicians, can be linked to a positive Diaceutics Signal alert (large stat, left-aligned, chain / link graphic right-aligned), and as the program matures, that figure is tracking upward.
of all invoiced client accounts
VP Marketing
If Your Drug Depends on a Biomarker Most Physicians Have Never Heard Of, We Know What Comes Next.
This therapy launched into a population so rare that almost no lab was testing for it correctly, no physician behavior had been established, and no commercial playbook had been written.
Your launch. Your biomarker. Your patients.
*Figure reflective of a fixed six-month comparison window, not a rolling calculation
Newsletter sign up
READY TO DO COMMERCIALIZATION DIFFERENTLY?
You might also be interested in?
Rethinking Drug Commercialization: Navigating a Shifting Biotech Investment Landscape
Explore strategies for biotech commercialization amid evolving investment landscapes, focusing on precision and rare disease therapies. Join industry experts in navigating funding challenges and enhancing patient outcomes.